Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LuTectomy: 177Lu-PSMA-617 Prior to Prostatectomy
NCT04430192Phase 2Active, not recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Aug 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa), sponsored by Peter MacCallum Cancer Centre. Started Aug 2020; status: active, not recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04430192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04430192.